The large research community in the Montpellier area focusing on cancer is involved with efforts to understand fundamental cancer mechanisms, with the goal of improving treatment. Its teams operate with various Montpellier institutes (IRCM, CBS, CRBM, IGMM, IGF, IGH, INM, IRIM, and LBN) and treatment centers (CHUs and ICM).
This community comprises 49 research teams operating in 10 laboratories (CBS, CRBM, IGF, IGH, IGMM, IRCM, IRIM, IRMB, LPHI, PhyMedExp) and 2 treatment centers (CHUs and ICM).
The community’s excellence is well recognized for the quality of its research, as well as for the certifications it has earned, such as SIRIC (Integrated Cancer Research Site) certification in 2013 with the “Montpellier Cancer SIRIC” project (INCa, DGOS, Aviesan) as well as Aviesan certification in 2017 of the EvoCan
Hospital-University Federation (FHU).
The Montpellier Cancer SIRIC is one of eight centers in France. It is based on the “Comprehensive Cancer Center” model used in the United States, with a single site uniting all the medical services, multidisciplinary research teams, and high technology resources and platforms to offer the best possible global care for patients. Certification was renewed in 2018 to establish a structure based on three main axes: colorectal cancer, radiation therapy, and genome integrity/ resistance to treatment.
In a complementary and coordinated effort, the FHU focuses on themes related to heterogeneity and tumor heteroclonality, a major challenge to be met with respect to therapeutics and diagnostics.